These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Assessment of serum levels of adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) in stable and unstable angina and acute myocardial infarction]. Bossowska A; Kiersnowska-Rogowska B; Bossowski A; Galar B; Sowiński P Przegl Lek; 2003; 60(7):445-50. PubMed ID: 14750416 [TBL] [Abstract][Full Text] [Related]
3. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Mulvihill NT; Foley JB; Murphy RT; Curtin R; Crean PA; Walsh M Heart; 2001 Jun; 85(6):623-7. PubMed ID: 11359739 [TBL] [Abstract][Full Text] [Related]
4. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome. Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608 [TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Leclerc JR Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of selected adhesion molecules in patients with coronary artery disease. Mizia-Stec K; Zahorska-Markiewicz B; Mandecki T; Janowska J; Szulc A; Jastrzebska-Maj E Int J Cardiol; 2002 May; 83(2):143-50. PubMed ID: 12007686 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
8. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074 [TBL] [Abstract][Full Text] [Related]
9. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530 [TBL] [Abstract][Full Text] [Related]
10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
11. Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Soeki T; Tamura Y; Shinohara H; Sakabe K; Onose Y; Fukuda N Int J Cardiol; 2003 Aug; 90(2-3):261-8. PubMed ID: 12957760 [TBL] [Abstract][Full Text] [Related]
13. The effects of pentoxifylline on circulating adhesion molecules in critically ill patients with acute renal failure treated by continuous veno-venous hemofiltration. Boldt J; Müller M; Heesen M; Martin K; Hempelmann G Intensive Care Med; 1996 Apr; 22(4):305-11. PubMed ID: 8708167 [TBL] [Abstract][Full Text] [Related]
14. The Mechanism of Inflammatory Factors and Soluble Vascular Cell Adhesion Molecule-1 Regulated by Nuclear Transcription Factor NF- Su Q; Zhang L; Qi Z; Huang B J Immunol Res; 2022; 2022():6137219. PubMed ID: 35942210 [TBL] [Abstract][Full Text] [Related]
15. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease. Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549 [TBL] [Abstract][Full Text] [Related]
16. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. O'Malley T; Ludlam CA; Riemermsa RA; Fox KA Eur Heart J; 2001 Jul; 22(14):1226-34. PubMed ID: 11440495 [TBL] [Abstract][Full Text] [Related]
17. The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes. Iliodromitis EK; Andreadou I; Markantonis-Kyroudis S; Mademli K; Kyrzopoulos S; Georgiadou P; Kremastinos DT Thromb Res; 2007; 119(2):167-74. PubMed ID: 16545434 [TBL] [Abstract][Full Text] [Related]
18. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Okmen E; Cakmak M; Tartan Z; Cam N Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426 [TBL] [Abstract][Full Text] [Related]
19. Levels of certain endothelial biomarkers during the acute phase and convalescence in patients with different severity of Mediterranean spotted fever. Baltadzhiev IG; Murdjeva MA Folia Med (Plovdiv); 2013; 55(3-4):17-25. PubMed ID: 24712278 [TBL] [Abstract][Full Text] [Related]